On January 8th, Gelonghui reported that YSB (9885.HK) announced on the Stock Exchange that it repurchased a total of 0.2 million shares in the market on January 6th and January 7th, at a total cost of 1.1375 million Hong Kong dollars. YSB stated in the announcement that the company believes the current stock price is below its intrinsic value and does not fully reflect the business outlook. The company also indicated in the announcement that it may conduct further buybacks, demonstrating confidence in its business prospects and outlook. Recently, the General Office of the State Council released the "Opinions on Deepening the Reform of Drug and Medical Instrument Supervision and Promoting the High-Quality Development of the Pharmaceutical Industry," proposing 24 reform measures, including "supporting wholesale enterprises in effectively integrating warehousing resources and transportation resources, building a multi-warehouse coordinated Logistics management model," "enhancing the level of information technology in the pharmaceutical industry, strengthening the construction of a full-chain drug traceability system, and gradually achieving traceability throughout the production, circulation, and usage process," "increasing support for the research and innovation of Traditional Chinese Medicine," "actively supporting the promotion and use of medical instruments," and "optimizing drug and medical instrument registration and inspection," among others. A new round of policy benefits is being concentrated and released, which is Bullish for the development of new business formats in pharmaceutical circulation. Industry insiders believe that the future direction of policies will likely focus on supporting the prosperity and diversification of the industry and strengthening integration and regulation, with leading companies that have higher professionalism and standards benefiting in the long term. As a leader in digital pharmaceutical circulation services outside hospitals, YSB has a first-mover advantage with a solid market foundation. In recent years, it has built its own warehousing and Logistics nationwide, actively laid out Traditional Chinese Medicine, pharmacy clinic Saas, and clinic POCT testing business. Benefiting from multiple rounds of policy dividends, it will have the opportunity to continue expanding its business advantages, and future performance is worth looking forward to.